Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial

Circulation

Volumn 97, Issue 17, 1998, Pages 1702-1707

  Mark, Daniel B ^a   Cowper, Patricia A ^b   Berkowitz, Scott D ^b   Davidson Ray, Linda ^b   Delong, Elizabeth R ^b   Turpie, Alexander G G ^b   Califf, Robert M ^b   Weatherley, Beth ^b   Cohen, Marc ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Angina; Anticoagulants; Coronary disease; Cost benefit analysis

Indexed keywords

ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; THROMBOPLASTIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNITED STATES; UNSTABLE ANGINA PECTORIS;

EID: 0032485914     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.17.1702     Document Type: Article

References (8)

1. Braunwald E, Mark DB, Jones RH, Cheitlin MD, Fuster V, McCauley K, Edwards C, Green LA, Mushlin AI, Swain JA, Smith EE III, Cowan M, Rose GC, Concannon CA, Grines CL, Brown L, Lytle BW, Goldman L, Topol EJ, Willerson JT, Brown J, Archibald N. Unstable angina: diagnosis and management. Agency for Health Care Policy and Research; 1994. AHCPR publication 94-0682.
2. Waters DD, Azar RR. Low molecular-weight heparins for unstable angina: a better mousetrap? Circulation. 1997;96:3-5.
3. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell G, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F, for the ESSENCE Study Group. Enoxaparin (low-molecular-weight heparin) versus unfractionated heparin for unstable angina and non-Q-wave myocardial infarction: primary endpoint results from the ESSENCE trial. N Engl J Med. 1997;337:447-452.
4. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia, Pa: Lippincott- Raven: 1997:1033-1062.
5. Klein W, Buchwald A, Hillis SE, Monrad S, Seinz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K, for the FRIC Investigators. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Disease Study (FRIC). Circulation. 1997;96:61-68.
6. The FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561-568.
7. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990;113:147-154.
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.